Patrícia Silva, PhD,  director of science content—

First Allied Securities hosted its annual national adviser conference this summer where 1,100 attendees participated not only in education, training, and networking, they also raised $72,000 for cystic fibrosis (CF) research through donations for the Cystic Fibrosis Foundation (CFF). An important part of the conference was the fundraising effort…

Sophia Genetics and Devyser announced a partnership to simplify the adoption of next-generation DNA sequencing (NGS) for routine diagnostic laboratories. According to the terms of the agreement, Sophia Genetics will use its advanced analytical platform, Sophia DDM, to support Devyser’s NGS diagnostic kits for cystic fibrosis (Devyser CFTR) and hereditary breast…

Kary Coleman, director of development and alumni relations at Penn State University’s New Kensington campus, was honored as one of Pittsburgh’s 50 Finest in 2016 by  WHIRL Magazine and the Cystic Fibrosis Foundation (CFF) of Western Pennsylvania for raising more than $6,000 in six months — 153 percent of the…

Spyryx Biosciences recently announced that Dr. Alistair Wheeler is joining the company as its new chief medical officer. Spyryx, a clinical-stage biopharma specializing in therapeutics for respiratory diseases, is currently evaluating a potential treatment for cystic fibrosis (CF) in early clinical testing. Wheeler will be responsible for all aspects of clinical and medical processes and associated regulatory…

Pulmatrix‘s inhaled PUR1900 for treating pulmonary fungal infections in patients with cystic fibrosis(CF) has received orphan drug status by the U.S. Food and Drug Administration (FDA). The designation was granted “based on a plausible hypothesis that (PUR1900) may be clinically superior to the same drug that is already approved for the same…

A team of scientists from Ulster University, in Northern Ireland, United Kingdom, have joined a nearly $980,000  global research study seeking alternative treatment options for patients with cystic fibrosis-related diabetes (CFRD). The new three-year Strategic Research Centre (SRC) study is the first of its kind funded by the Cystic Fibrosis Trust…

The San Diego Chapter of the Cystic Fibrosis Foundation will host its inaugural Surf for CF day on the beach at La Jolla Shores on Sept. 24, raising awareness and funds for cystic fibrosis (CF). The two-part event will feature free surf lessons for 25 cystic fibrosis patients in the morning,…

Patients and loved ones affected by the burden of cystic fibrosis (CF) may want to take action and do something to fight this chronic and progressive disease. However, it’s not always easy to find ways to do so. Becoming an advocate for cystic fibrosis may be an option for some…

Savara Pharmaceuticals announced that it has finished with the steps necessary to fully acquire Serendex Pharmaceuticals, strengthening its position as a developer of therapies for rare respiratory diseases. Savara’s pipeline of products now includes these three, according to a press release: Alveodex, a proprietary nebulized formulation of Factor VIIa (recombinant human FVIIa),…

Alaxia SAS announced that it has received $1.7 million from the Cystic Fibrosis Foundation Therapeutics (CFFT), the non-profit drug discovery and development arm of the Cystic Fibrosis Foundation (CFF), to support and advance a first clinical study of its inhaled antimicrobial drug candidate, ALX-009, as a therapy for people with cystic fibrosis…